Q2 2025 · 13F-HR
ACUTA CAPITAL PARTNERS, LLCholdings as filed
Filed 2025-08-14 · accession 0001104659-25-078732
$71.6M
Reported value
28
Positions
2025-06-30
Period end
The Brief · ACUTA CAPITAL PARTNERS, LLC · Q2 2025
AI · grounded in 13F
ACUTA CAPITAL PARTNERS, LLC established a new position in OCUL valued at $9.4M. The fund also initiated new stakes in CDTX for $8.7M and WHWK for $6.4M. Additional new positions include SLNO at $5.3M and TRML at $4.5M. Total assets under management stand at $71.6M across 28 positions.
Holdings as filed
| CUSIP | Ticker | Issuer | Value | % port. | Shares | Class | Voting |
|---|---|---|---|---|---|---|---|
| 67576A100 | OCUL | OCULAR THERAPEUTIX INC | $9.4M | 13.1% | 1,014,940 | Common | SOLE |
| 171757206 | CDTX | CIDARA THERAPEUTICS INC | $8.7M | 12.2% | 179,569 | Common | SOLE |
| 00032Q104 | WHWK | WHITEHAWK THERAPEUTICS INC | $6.4M | 8.90% | 3,410,402 | Common | SOLE |
| 834203309 | SLNO | SOLENO THERAPEUTICS INC | $5.3M | 7.42% | 63,436 | Common | SOLE |
| 89157D105 | TRML | TOURMALINE BIO INC | $4.5M | 6.33% | 283,682 | Common | SOLE |
| 04351P101 | ASNDUSD | ASCENDIS PHA-ADR | $3.9M | 5.44% | 22,576 | Common | SOLE |
| 457669307 | INSM | INSMED INC | $3.7M | 5.21% | 37,070 | Common | SOLE |
| 04016X101 | ARGX | ARGEN SE - ADR | $3.7M | 5.16% | 6,702 | Common | SOLE |
| 74006W207 | PRAX | PRAXIS PRECISION MEDICINES I | $3.1M | 4.35% | 74,087 | Common | SOLE |
| G50871105 | JAZZ | JAZZ PHARMACEUTICALS PLC | $2.8M | 3.89% | 26,283 | Common | SOLE |
| 89532M101 | TRVI | TREVI THERAPEUTICS INC | $2.7M | 3.77% | 493,735 | Common | SOLE |
| H5870P102 | OCS | OCULIS HOLDING AG | $2.1M | 2.89% | 106,718 | Common | SOLE |
| 76155X100 | RVMD | REVOLUTION MEDICINES INC | $2.0M | 2.86% | 55,693 | Common | SOLE |
| G4444H101 | BBOT | HELIX ACQUISITION CORP II | $2.0M | 2.78% | 187,257 | Common | SOLE |
| 880881107 | 430 | TERNS PHARMACEUTICALS INC | $1.7M | 2.42% | 463,864 | Common | SOLE |
| 86889P208 | SRZN | SURROZEN, INC. | $1.5M | 2.12% | 170,000 | Common | SOLE |
| 10919W405 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $1.3M | 1.77% | 48,474 | Common | SOLE |
| 877619106 | TSHA | TAYSHA GENE THERAPIES INC | $1.1M | 1.57% | 485,669 | Common | SOLE |
| 00973Y108 | AKRO | AKERO THERAPEUTICS INC | $1.1M | 1.47% | 19,772 | Common | SOLE |
| 98985Y108 | ZYME | ZYMEWORKS INC | $1.0M | 1.47% | 83,655 | Common | SOLE |
| 53635D202 | LQDA | LIQUIDIA CORPORATION | $945,415 | 1.32% | 75,876 | Common | SOLE |
| 90400D108 | RARE | ULTRAGENYX PHARMACEUTICAL INC | $865,877 | 1.21% | 23,814 | Common | SOLE |
| 92337C203 | VSTM | VERASTEM INC | $624,218 | 0.87% | 150,414 | Common | SOLE |
| 359616109 | FULC | FULCRUM THERAPEUTICS INC | $410,392 | 0.57% | 59,650 | Common | SOLE |
| 90466Y202 | UNCY | UNICYCIVE THERAPEUTICS INC | $300,028 | 0.42% | 62,899 | Common | SOLE |
| 75383L102 | RAPP | RAPPORT THERAPEUTICS INC | $227,400 | 0.32% | 20,000 | Common | SOLE |
| 04317A107 | ARTV | ARTIVA BIOTHERAPEUTICS INC | $68,639 | 0.10% | 45,456 | Common | SOLE |
| 67080N119 | NUVB/WS | NUVATION BIO INC -CW27 | $24,516 | 0.03% | 90,832 | Common | SOLE |
Source: SEC EDGAR · raw 13F holdings as filed. The Class column shows the option type when reported (Put/Call) or Common when the issuer's equity is held directly. 13F discloses long positions only.